Mammen Mathai
Known title: DirectorCIK: 0001421050
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Transaction History
| TXG | ▲ Buy | Grant | 8,649 | $0 | 6/11/2024 | View on chart |
| TXG | ▲ Buy | Grant | 1,865 | $0 | 6/14/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 33,000 | $1.7M | 5/11/2023 | View on chart |
| TXG | ▲ Buy | Option Exercise | 200,000 | $232K | 5/11/2023 | View on chart |
| TXG | ▲ Buy | Grant | 2,120 | $0 | 6/15/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 7,740 | $0 | 2/15/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 3,366 | $558K | 2/15/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 7,418 | $0 | 2/14/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 2,335 | $394K | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.